ADK.V - DIAGNOS Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.0300
0.0000 (0.00%)
At close: 3:53PM EST
Stock chart is not supported by your current browser
Previous Close0.0300
Open0.0300
Bid0.03 x 0
Ask0.04 x 0
Day's Range0.0300 - 0.0300
52 Week Range0.0300 - 0.1100
Volume273,000
Avg. Volume137,000
Market Cap6.388M
Beta (3Y Monthly)3.11
PE Ratio (TTM)N/A
EPS (TTM)-0.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire18 days ago

    DIAGNOS Welcomes Dr. Jean-Francois Yale to the Board of Directors

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the appointment of Dr. Jean-Francois Yale to its board of directors. Dr. Yale is an endocrinologist, currently professor of medicine at the McGill University Department of Medicine. Dr. Yale chaired the Clinical and Scientific Section of the Canadian Diabetes Association from 1992-1994 as well as the Expert Committee that published the 2001 Clinical Practice Guidelines for the Prevention and Management of Diabetes.

  • GlobeNewswire25 days ago

    DIAGNOS Announces an Extension to the Diabetic Retinopathy Screening Services Assisted by Artificial Intelligence (AI) at the CHUM

    DIAGNOS Inc. (“DIAGNOS” or the “Company”) (TSX Venture Exchange: ADK) (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today, further to our initial news release dated June 5th, 2018, the extension through May 2019 of the technological showcase for the automated detection of Diabetic Retinopathy at the Centre Hospitalier de l’Université de Montréal (CHUM). DIAGNOS will continue screening for diabetic retinopathy at the CHUM until the end of May 2019.

  • GlobeNewswire2 months ago

    DIAGNOS Announces Closing of Private Placement

    BROSSARD, Quebec, Dec. 12, 2018 -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health.

  • GlobeNewswire2 months ago

    DIAGNOS is announcing a collaboration with ÉTS on Automated detection and grading of Diabetic Retinopathy using Deep Convolutional Neural Networks, (CNN) a new generation of Deep Learning Technique  

    BROSSARD, Quebec, Dec. 04, 2018 -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues.

  • GlobeNewswire3 months ago

    DIAGNOS Announces Final Closing of Private Placement

    BROSSARD, Quebec, Nov. 21, 2018 -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health.

  • GlobeNewswire3 months ago

    DIAGNOS Enters into a Shares for Debt Transaction

    DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces today it has entered into a shares for debt arrangement in which the Corporation is issuing 900,000 common shares (each a “Share”), at a deemed price of $0.05 per Share, in settlement for interests payable in the amount of $45,000 on outstanding unsecured convertible notes (each a “Note”) totaling $900,000. Satisfying this outstanding indebtedness with shares was undertaken in order to preserve the Corporation’s cash for operational purposes. Two Note holders eligible to receive common shares as part of the shares for debt transaction are considered “related parties” of the Corporation within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”).